Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$68.64 - $89.2 $455,495 - $591,931
6,636 New
6,636 $485,000
Q3 2023

Nov 14, 2023

BUY
$58.86 - $72.67 $372,760 - $460,219
6,333 New
6,333 $379,000
Q1 2023

May 15, 2023

SELL
$65.67 - $77.08 $4.29 Million - $5.03 Million
-65,280 Reduced 70.3%
27,583 $2.03 Million
Q4 2022

Feb 14, 2023

BUY
$61.72 - $96.74 $3.27 Million - $5.13 Million
52,980 Added 132.84%
92,863 $6.2 Million
Q2 2022

Aug 15, 2022

BUY
$74.52 - $117.06 $2.97 Million - $4.67 Million
39,883 New
39,883 $3.56 Million
Q4 2021

Feb 14, 2022

SELL
$127.69 - $165.85 $1.12 Million - $1.46 Million
-8,776 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$102.33 - $144.73 $898,048 - $1.27 Million
8,776 New
8,776 $1.22 Million
Q1 2021

May 17, 2021

SELL
$99.52 - $215.83 $638,420 - $1.38 Million
-6,415 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$80.55 - $106.05 $516,728 - $680,310
6,415 New
6,415 $638,000
Q2 2020

Aug 13, 2020

SELL
$68.28 - $123.65 $346,725 - $627,894
-5,078 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$63.37 - $107.88 $321,792 - $547,814
5,078 New
5,078 $369,000
Q3 2019

Nov 14, 2019

SELL
$86.25 - $120.16 $2.61 Million - $3.63 Million
-30,205 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$107.38 - $129.34 $2.79 Million - $3.36 Million
-25,956 Reduced 46.22%
30,205 $3.45 Million
Q1 2019

May 14, 2019

SELL
$105.93 - $142.47 $10.4 Million - $14 Million
-98,374 Reduced 63.66%
56,161 $7.06 Million
Q4 2018

Feb 14, 2019

BUY
$128.36 - $272.13 $19.7 Million - $41.8 Million
153,440 Added 14012.79%
154,535 $21 Million
Q3 2018

Nov 14, 2018

SELL
$211.18 - $274.49 $964,459 - $1.25 Million
-4,567 Reduced 80.66%
1,095 $301,000
Q2 2018

Aug 14, 2018

BUY
$150.77 - $207.98 $853,659 - $1.18 Million
5,662 New
5,662 $1.17 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.77B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.